Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Sudeep Pharma Ltd. Share Price
Day's Range
Day's Range
Low
₹858.55
High
₹888.35
Price Summary
| Previous Close | ₹869.00 |
|---|---|
| Day's Range | ₹858.55 - ₹888.35 |
| Open | ₹874.00 |
| 52 Week Range | ₹524.05 - ₹894.95 |
| Volume | 55,711 |
| Market Cap | ₹0.01 |
| Previous Close | ₹873.00 |
|---|---|
| Day's Range | ₹861.95 - ₹887.80 |
| Open | ₹874.00 |
| 52 Week Range | ₹524.95 - ₹893.40 |
| Volume | 4,827 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 484.13 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.17 |
| Price/Earning (TTM) | 56.57 |
| TTM EPS (₹) | 15.31 |
| P/E Ratio | 38.70 |
| Book Value(₹) | 11.07 |
| PAT Margin (%) | 26.64 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 28.50 |
| Trade Value ( ₹ in Lacs) | 42.14 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.17 |
| Price/Earning (TTM) | 56.57 |
| TTM EPS (₹) | 15.31 |
| P/E Ratio | 38.70 |
| Book Value(₹) | 11.07 |
| PAT Margin (%) | 26.64 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 28.50 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1575.46 | 5019.99 |
| Expenses | N/A | N/A |
| PBT | 578.54 | 1828.45 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 441.86 | 1387.29 |
About Sudeep Pharma Ltd.
| Founded | 1989 |
|---|---|
| Managing Director | Sujit Jaysukh Bhayani |
| NSE Symbol | SUDEEPPHRM |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,69,381.90 | 1,957.80 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,94,374.77 | 7,304.75 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,90,307.55 | 5,000.30 | 3,468.00 - 3,468.00 |
| Apollo Hospitals Enterprise Ltd. | 1,28,113.57 | 8,891.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,446.86 | 1,423.30 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,14,378.78 | 1,142.20 | 835.50 - 835.50 |
| Lupin Ltd. | 1,13,316.52 | 2,501.10 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,07,245.00 | 1,087.00 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,05,978.90 | 2,570.40 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 1,02,105.89 | 1,208.65 | 1,148.40 - 1,148.40 |
No Records Found
Latest News
Sudeep Pharma informs about closure of trading window
Pursuant to the Code of Conduct on Prevention of Insider Trading of the Company and SEBI (Prohibition of Insider Trading) Regulations, 2015, Sudeep Pharma has informed that the trading window for dealing in the securities of the Company shall be closed for designated persons from Wednesday, 1st July 2026 and shall remain closed till 48 hours after the declaration of the un-audited financial results of the Company for quarter ending on 30th June 2026 and other matters, if any. Accordingly, all Designated Persons and their immediate relatives, directly or indirectly, are prohibited to deal in the securities of the Company during this period. The date of the meeting of the Board of directors to approve the un-audited financial results of the company for the aforementioned quarter, shall be informed to the stock exchanges in due course.
The above information is a part of company’s filings submitted to BSE.
Sudeep Pharma informs about press release
Glenmark Pharmaceuticals informs about press release
Glenmark Pharmaceuticals has informed that, Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of RYALTRIS® (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. With this approval, RYALTRIS® is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.
Lupin informs about acquisition
Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, Lupin has informed that Lupin Inc. U.S.A., wholly owned subsidiary of the Company, has entered into a licensing agreement to grant an exclusive perpetual license for two of its oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), to Kaveri Therapeutics, Inc. U.S.A. (‘Kaveri’), in exchange for an 82.2% equity stake (Common Shares) in Kaveri. The details required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and the SEBI Master Circular dated January 30, 2026 (reference no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026), along with other applicable circulars, are set out in Annexure I. A press release regarding this arrangement is enclosed.
The above information is a part of company’s filings submitted to BSE.
Venus Remedies - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 1788.00 | 1371.30 | 30.39 | 1788.00 | 1371.30 | 30.39 | 7687.30 | 6444.70 | 19.28 |
| Other Income | 25.50 | 27.20 | -6.25 | 25.50 | 27.20 | -6.25 | 114.60 | 157.70 | -27.33 |
| PBIDT | 391.10 | 206.50 | 89.39 | 391.10 | 206.50 | 89.39 | 1553.70 | 907.70 | 71.17 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PBDT | 391.10 | 206.50 | 89.39 | 391.10 | 206.50 | 89.39 | 1553.70 | 1006.80 | 54.32 |
| Depreciation | 65.10 | 59.50 | 9.41 | 65.10 | 59.50 | 9.41 | 246.90 | 216.20 | 14.20 |
| PBT | 326.00 | 147.00 | 121.77 | 326.00 | 147.00 | 121.77 | 1306.80 | 790.60 | 65.29 |
| TAX | 70.70 | 30.10 | 134.88 | 70.70 | 30.10 | 134.88 | 313.70 | 265.10 | 18.33 |
| Deferred Tax | -11.30 | -6.90 | 63.77 | -11.30 | -6.90 | 63.77 | -15.20 | 46.50 | -132.69 |
| PAT | 255.30 | 116.90 | 118.39 | 255.30 | 116.90 | 118.39 | 993.10 | 525.50 | 88.98 |
| Equity | 133.70 | 133.70 | 0.00 | 133.70 | 133.70 | 0.00 | 133.70 | 133.70 | 0.00 |
| PBIDTM(%) | 21.87 | 15.06 | 45.26 | 21.87 | 15.06 | 45.26 | 20.21 | 14.08 | 43.50 |
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Sudeep Pharma Ltd. is ₹869.00 as of 2026-07-21.
The market capitalisation of Sudeep Pharma Ltd. is ₹9,780.79 as of 2026-07-20.
The 1-year return of Sudeep Pharma Ltd. is % as of .
The P/E ratio of Sudeep Pharma Ltd. is 38.70 as of 2026-07-21.
The 52-week high and low of Sudeep Pharma Ltd. are ₹894.95 and ₹524.05, respectively, as of 2026-07-21.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
